One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Alopecia Treatment (Hair Loss) Market

[ 英語タイトル ] Alopecia Treatment (Hair Loss) Market - Growth, Trends, and Forecasts (2020 - 2025)


Product Code : MDHC0083305
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 114
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Aclaris Therapeutics Inc.
- Cipla Inc.
- Concert Pharmaceuticals Inc.
- Daiichi Sankyo Inc.
- GlaxoSmithKline PLC
- HCell Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- Sun Pharmaceuticals Industries Ltd

[Report Description]

Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues. A sedentary lifestyle and unhealthy diets are leading to loss of hair among masses. Furthermore, aging and hormonal imbalance, increasing chronic diseases like arthritis, cancer, hypertension, depression also leads to hair loss, especially among the middle-aged population. According to the American Hair Loss Association, androgenetic alopecia accounts for over 95% of hair loss in men. Over 800 thousand patients are seeking some kind of treatment for hair loss worldwide.

In recent years, many novel drugs have been approved by the regulatory bodies for the treatment of alopecia and many drugs are in pipeline, which are expected to receive approval in the near future. Concert Pharmaceuticals Inc. received fast track designation from the United States Food and Drug Administration, (FDA) for its novel product for the treatment of moderate-to-severe alopecia areata in January 2018. The launches of such novel products in the market is expected to drive the global alopecia treatment market growth in the near future.

Key Market Trends

Female is Expected to Hold Largest Share Over the forecast period

About one-third of women experience hair loss (alopecia) at some time in their lives. Among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hair loss in women often has a greater impact than hair loss does on men, because it's less socially acceptable for them. Androgenetic alopecia is the most common cause of hair loss in women. Alopecia can severely affect a woman's emotional well-being and quality of life. Although Alopecia is more common in male than female, the female has the largest share in the market owing to the factors such as high awareness levels coupled with increased frequency of Polycystic Ovary Syndrome (PCOS) causing a hormonal imbalance that leads to androgenetic alopecia.

North America Region Holds the Largest Market Share of Alopecia Treatment (Hair Loss) Market

North America dominates the Alopecia Treatment (Hair Loss) market due to the presence of technologically advanced healthcare infrastructure, high disposable income, and availability of novel therapeutics options pertaining to the treatments. According to the United States National Library of Medicine, Alopecia areata affects 1 in every 500 to 1,000 people in the United States. It is one of many recognized forms of alopecia, alopecia areata is the second most common form after androgenetic alopecia. Alopecia areata affects men and women equally, and it can occur in people of any ethnic background.

Therefore, the high prevalence and the proportionally high treatment rates pertaining to hair loss in the U.S. are high major drivers for the North American market.

Competitive Landscape

Some of the prominent industry players operating in total Alopecia Treatment (Hair Loss) market include Sun Pharmaceuticals Industries Ltd., Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc. The development of advanced products for better outcomes and rigorous marketing is one of the competitive strategies adopted by the market players. In 2018, HCell Inc., a biotechnology company received orphan drug designation (ODD) for its product from the FDA. Furthermore, in 2017, Perrigo Company PLC. Launched over-the-counter Women's Rogaine, which helps to regrow hair on top of the scalp.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Alopecia
4.2.2 Increasing R&D Initiatives and New Product Launches and Approvals
4.3 Market Restraints
4.3.1 Patent Expiry of Many Blockbuster Drugs
4.3.2 Side Effects Associated with the Available Hair Loss Treatment Therapies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Disease Type

5.1.1 Androgenic Alopecia
5.1.2 Alopecia Areata
5.1.3 Ciatricial Alopecia
5.1.4 Traction Alopecia
5.1.5 Alopecia Totalis
5.2 By Gender


5.2.1 Male
5.2.2 Female
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Topical
5.3.3 Injectable
5.4 By Distribution Channel
5.4.1 Hospitals
5.4.2 Retail Pharmacies
5.4.3 Online Pharmacies
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aclaris Therapeutics Inc.
6.1.2 Cipla Inc.
6.1.3 Concert Pharmaceuticals Inc.
6.1.4 Daiichi Sankyo Inc.
6.1.5 GlaxoSmithKline PLC
6.1.6 HCell Inc.
6.1.7 Johnson & Johnson
6.1.8 Merck & Co. Inc.
6.1.9 Sun Pharmaceuticals Industries Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+